Federal Hemp Update — Congressional Researchers Note FDA Still Has Not Published Required Cannabinoid Lists and "Container" Guidance

This is a CLOUDWIRE monitoring update. The Congressional Research Service (CRS) — the nonpartisan research arm of Congress — has published an updated report noting that the U.S. Food and Drug Administration has still not published the cannabinoid lists and product-container guidance that Congress directed it to issue, more than six months past the statutory 90-day deadline.

Nothing about this changes federal law, and nothing about it changes what is legal to sell today. But it matters for a practical reason: those FDA lists and definitions are the pieces operators would use to determine which products fall inside or outside the new federal hemp definition taking effect November 12, 2026. Without them, compliance planning is being done against an incomplete federal record.

What Congress Told FDA to Do

Public Law 119-37 — the FY2026 Agriculture appropriations law signed on November 12, 2025 — amended the statutory definition of hemp at 7 U.S.C. § 1639o. That amended definition takes effect November 12, 2026.

The same law directed FDA, in consultation with other relevant federal agencies, to publish within 90 days of enactment:

1. A list of all cannabinoids known to FDA to be capable of being naturally produced by a cannabis plant, based on peer-reviewed literature;
2. A list of all tetrahydrocannabinol-class cannabinoids known to the agency to be naturally occurring in the plant; and
3. A list of all other known cannabinoids with effects similar to — or marketed as having effects similar to — THC-class cannabinoids.

FDA was also directed, on the same 90-day timeline, to provide additional information and specificity about the term "container" as it applies to THC serving-size limits. The statute defines "container" as the innermost wrapping, packaging, or vessel in direct contact with a final hemp-derived cannabinoid product — a jar, bottle, bag, box, packet, can, carton, or cartridge.

That 90-day window closed on February 10, 2026.

What CRS Said

In an updated version of CRS report IF13136, Changes to the Statutory Definition of Hemp and Implications for Agricultural Policy, congressional researchers state that the law requires FDA to consult with relevant federal agencies and publish the required information within 90 days of enactment — and that, as of August 2026, it has not been published.

This is not the first time CRS has flagged the issue; researchers noted the same gap in an earlier analysis published in May 2026.

The updated report also summarizes the ongoing policy dispute. It notes that some stakeholders — including attorneys general in several states — have opposed delaying the effective date of the new hemp definition, while some hemp industry groups have opposed the definitional changes and prefer regulation through agencies like FDA. CRS concludes that lawmakers may consider whether to further amend the statutory definition or implement regulatory frameworks for certain hemp products.

What This Is — and What It Is Not

CRS reports are nonpartisan analyses prepared for Members and committees of Congress. They carry no legal force. An updated CRS report does not:

• Change the November 12, 2026 effective date;
• Delay, suspend, or narrow any federal restriction;
• Constitute an FDA rule, guidance document, or enforcement position;
• Affect Texas state law or DSHS enforcement in any way.

Equally, FDA's non-publication does not pause the statute. The amended federal hemp definition takes effect on its own terms on November 12, 2026 whether or not FDA publishes the lists first, unless Congress acts and the President signs a change into law.

What It Means for Operators and Consumers

Texas retailers and manufacturers: Nothing changes today. The Texas restrictions that took effect July 31, 2026 remain fully operative. Continue current compliance procedures. The practical takeaway is that the federal cannabinoid classification questions many operators are trying to answer ahead of November 12 do not yet have an authoritative federal answer.

Distributors and wholesalers: Inventory and sourcing decisions targeting the post-November 12 window are being made without the FDA cannabinoid lists. Product-by-product classification under the new definition — particularly for cannabinoids whose natural-occurrence status is contested — carries added uncertainty. Documenting the basis for classification decisions is prudent.

Online sales: Interstate shipments remain subject to both the destination state's law and the federal definition as it will apply after November 12. The absence of an FDA "container" definition leaves serving-size and packaging compliance questions unresolved for multi-serving and multi-unit formats.

Consumers: No product legality changed as a result of this report. Availability in Texas continues to be governed by the state restrictions currently in effect.

What Is Still Pending

• FDA publication of the three cannabinoid lists and the "container" guidance — no announced date.
• House action on H.R. 6500 and the Section 2019 hemp extension. The House is in recess; the Senate passed the measure 90–6 on August 8, 2026.
• Preliminary-injunction proceedings in Monti v. Garcia, No. 3:26-cv-00254 (S.D. Tex., Galveston Division), where an emergency TRO was denied in August.
• The separate federal hemp-retailer complaint filed August 21, 2026 in the Western District of Texas. No order has been signed in that case.
• Texas 15th Court of Appeals action in THBC v. DSHS.

What CLOUDWIRE Is Watching Next

1. Any Federal Register publication by FDA of the required cannabinoid lists.
2. Any FDA guidance defining or clarifying "container" for THC serving-size purposes.
3. House return from recess and floor action on H.R. 6500, including any amendment or motion affecting Section 2019.
4. Presidential signature or veto of any enacted version of H.R. 6500.
5. Signed orders in either pending federal Texas hemp case.
6. Any new Texas DSHS notice, recall, product detention, or Texas Register publication.
7. Further CRS or congressional committee activity on the hemp definition.

Bottom Line

Congress's own research service has now twice documented that FDA has not delivered the cannabinoid lists and container guidance the law required by February 10, 2026. That is a real compliance problem for an industry facing a November 12 federal deadline — but it is not a legal change. The new federal hemp definition is still scheduled to take effect November 12, 2026. The Senate's proposed extension to December 11 is still a proposal. Texas's July 31 restrictions are still in effect. CLOUDWIRE will publish a full update if FDA publishes the required lists, if the House acts on the extension, or if any court signs an order.

This article is provided for general informational purposes only. It does not constitute legal advice and does not determine whether a particular product, transaction, or business practice complies with federal, state, or local law.

Follow the Federal Hemp Deadline

CLOUDWIRE tracks federal hemp legislation, Texas state enforcement, and consumer-relevant compliance updates as they develop. Subscribe to receive email alerts when meaningful legislative or regulatory developments occur.

Official Sources

• Congressional Research Service, Changes to the Statutory Definition of Hemp and Implications for Agricultural Policy, IF13136 (Congress.gov)
• CRS report IF13136 — full text PDF (Congress.gov)
• Public Law 119-37 (govinfo.gov)
• H.R. 6500 — Continuing Appropriations and Extensions Act, 2027, official bill summary (govinfo.gov)
• U.S. Food and Drug Administration
• Texas DSHS — Consumable Hemp Program
• PACER — Public Access to Court Electronic Records
• Supplemental — Marijuana Moment, "Congressional Researchers Call Out FDA For Not Publishing Hemp Cannabinoid Lists And Guidance On Product Containers That's Six Months Overdue" (Aug. 24, 2026)